LATS2 and cancer: Dasatinib shows the potential to modulate anticancer immunity (Figure 6B), and selectively impairs LATS2-altered MPM cells (Figure 6C), in line with the evidence that Dasatinib enhances anti-PDL1 efficacy in cancer [30].